Men vs women in emerging markets
Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging markets.
While a wide-range range of societal and economic factors influence health outcomes, one of the most significant factors is gender. In addition to overall morbidity and mortality, certain health issues are more commonly associated with one gender. But while biology plays a role, it is predominantly the way in which society structures and shapes men’s and women’s lives that result in health inequalities. Gender norms, roles and expectations vary between cultures, particularly in emerging markets, and affect the way in which health care is accessed. Our latest interactive infographic compares the lives of men vs women in the BRIC emerging markets, and explores how societal factors impact their respective health outcomes.
Nutrition Market in Brazil: Growth Against the Odds
Published in eyeforpharma June 2017 by Marc Yates
Until the recession of 2014, Brazil saw a sustained period of strong growth in the functional foods and nutritional supplements market, albeit from a low base. The wealth gap was closing and a burgeoning, better-educated middle class with a rising disposable income was increasingly interested in nutrition products, both as lifestyle accessory and aid to healthier, longer lives.
Interactive infographic: LATAM
An overview of the six most-commonly researched, largest pharma markets in Latin America
The LATAM region's largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With pharmaceutical sales of more than $64bn, it is an attractive market for pharma, however it is also one in which each market differs in terms of opportunities and challenges.
HCV LATAM infographic
Hepatitis C virus (HCV) is well recognised as a worldwide problem with approximately 150 million chronic carriers. If left untreated HCV becomes a chronic health problem putting a huge strain on national healthcare resources. Within Latin America studies suggest that around 4.6 million people are currently infected with chronic HCV.
Click here to view our latest infographic, in which we provide an introduction to the HCV LATAM patient.
Find out more about our experience in emerging markets »
Sign up to receive Rapport Rapport is our e-newsletter and online resource for sharing our expertise and experience in global healthcare market research. Sign up here »
5 years on from the Brazilian Generics Drugs Act, is there still an opportunity for branded originator drugs?
Published in eyeforpharma 10 November by Paul Reed
In 2009 the Brazilian government passed the Generics Drugs Act; one of numerous initiatives intended to reduce spend on originator branded drugs, whilst boosting generic drug prescription and supporting the domestic drug industry.
5 years on from the act, how successful have the Brazilian government been in advancing the local pharmaceutical players while reducing branded originator drugs spend? And importantly, is there still an opportunity for branded originator drugs?